Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 May 19];8(6):s477. Available from: https://skin.dermsquared.com/skin/article/view/3079